Kato K, Niitani H, Kanazawa T, Shimomura K, Toyama S
J Cardiovasc Pharmacol. 1986;8 Suppl 11:S154-9. doi: 10.1097/00005344-198511001-00028.
Efficacy and safety of the new beta-adrenoceptor antagonist, bisoprolol, in treatment of stable angina pectoris were studied in 36 patients using two types of single-blind design. After 2 weeks of therapy with bisoprolol in doses of 5 mg to 10 mg a day, exercise duration and time to 1 mm of ST-segment depression were significantly prolonged in 7 out of 10 patients who had a positive treadmill exercise test before bisoprolol. Bisoprolol significantly reduced heart rate (HR), systolic blood pressure (SBP), and rate-pressure product (RPP) at peak exercise, which would account for the beneficial effect of bisoprolol on exercise tolerance. Bisoprolol also produced improvement in symptoms for 26 patients with stable effort angina, as indicated by decreased frequency of anginal attacks and nitroglycerin consumption with a once-a-day regimen. Ten patients had no attacks after 5 mg of bisoprolol, and three more did not develop angina after increasing the dose to 10 mg a day. These results suggest that bisoprolol will be a promising, efficacious, and safe drug for the treatment of stable angina pectoris.
采用两种单盲设计方法，对36例患者研究了新型β-肾上腺素能受体拮抗剂比索洛尔治疗稳定型心绞痛的疗效和安全性。在每天服用5毫克至10毫克比索洛尔治疗2周后，在比索洛尔治疗前进行平板运动试验呈阳性的10例患者中，有7例患者的运动持续时间和ST段压低1毫米的时间显著延长。比索洛尔在运动高峰时显著降低心率（HR）、收缩压（SBP）和心率血压乘积（RPP），这可以解释比索洛尔对运动耐量的有益作用。比索洛尔还使26例稳定劳力性心绞痛患者的症状得到改善，每日一次给药方案使心绞痛发作频率和硝酸甘油消耗量降低即可表明这一点。10例患者服用5毫克比索洛尔后未发作，另外3例患者将剂量增至每日10毫克后也未发生心绞痛。这些结果表明，比索洛尔将是一种有前途且有效、安全的治疗稳定型心绞痛的药物。
